In a new deal, Denmark-based Leo Pharma is acquiring Replay — and its “next-generation gene therapy platform” — with an eye toward developing a topical treatment for dystrophic epidermolysis bullosa (DEB), a rare genetic disease causing extremely fragile skin. The gene therapy company, based in the U.S., is…